The present application aims at using neuroimmune approaches to understand the neurobiological basis of behavior. The objective is to study how deregulated interactions between the nervous and immune systems contribute to co morbidity of depression and pain. Depressive disorders and chronic pain represent two major health burdens in the Western world. Chronic pain predisposes to depression and vice versa, and 30-60% of the cases suffer from both depression and chronic pain. The broad question we seek to answer using a neuroimmune approach is: Why is chronic pain a risk factor for depression, and vice versa? Peripheral inflammation causes sickness behavior that can culminate into depressive behavior when the tryptophan metabolizing enzyme 2,3 indoleamine dioxygenase (IDO) is up regulated. We recently made the exciting discovery that an intracellular protein known as G protein coupled receptor kinase 2 (GRK2) possesses anti-inflammatory properties and acts as a molecular switch that regulates transition from acute to chronic pain. Our newest preliminary data indicate that low GRK2 enhances IDO expression by microglia in vitro. This proposal will test the completely novel concept that GRK2 is a critical molecule that explains the shared risk for developing depression and chronic pain. We have shown that chronic neuropathic pain or inflammation significantly reduces GRK2 in microglia from rodents. This finding is clinically important because low GRK2 in microglia is sufficient to transform transient inflammatory pain into chronic pain. We also showed that low GRK2 augments pro-inflammatory cytokine production and increases activation of p38 in vivo and in vitro. Moreover, we have preliminary data that p38 activity regulates IDO expression, which is key to development of inflammation-associated depressive-like behavior. We hypothesize that the reduction in microglial GRK2 caused by chronic neuropathic pain increases microglial p38 activity, pro-inflammatory cytokine production and IDO expression, thereby acting as risk factor for prolonged depressive-like and pain behaviors. To test this hypothesis, we will answer the following specific questions: 1. Is development of neuropathic pain and depressive-like behavior temporally related to the inflammation-induced reduction in GRK2 and the increase in IDO in CNS microglia/mf? 2. Is low GRK2 a risk factor for development of depressive-like behaviors and what is the mechanism? We will use mice with low GRK2 in microglia that we have generated using Cre-Lox technology. 3. Are comorbid depression and chronic pain both prevented by treatments that interfere with the loop of reduced GRK2, increase in p38 activity and upregulation of IDO? Collectively, these innovative experiments will identify low GRK2 as a completely novel risk factor for development of comorbid depression and chronic pain via a p38/cytokine/IDO-dependent pathway. Identification of these new molecular mechanisms underlying comorbid depression and pain is needed for effective development of novel prevention and therapeutic strategies.

Public Health Relevance

The proposed research is relevant and significant for public health because we anticipate discovering a novel shared neuroimmune risk factor for chronic pain and depression associated with nerve injury. The key is an enzyme known as G protein coupled receptor kinase-2. Delineation of neuroimmune pathways that mediate the effect of low GRK2 as a major risk factor in depression and pain is ultimately expected to enable development of novel therapeutic strategies aimed at treating the cause of these frequently co-occurring disorders. The proposed research is likely to have a major impact on the mission of the National Institute of Neurological Disorders and Stroke that is to reduce the burden of neurological disorders, including chronic pain.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01NS073939-02
Application #
8286972
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Porter, Linda L
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2012
Total Cost
Indirect Cost
Name
University of Illinois Urbana-Champaign
Department
Pathology
Type
Schools of Medicine
DUNS #
041544081
City
Champaign
State
IL
Country
United States
Zip Code
61820
Krukowski, Karen; Eijkelkamp, Niels; Laumet, Geoffroy et al. (2016) CD8+ T Cells and Endogenous IL-10 Are Required for Resolution of Chemotherapy-Induced Neuropathic Pain. J Neurosci 36:11074-11083
Singhmar, Pooja; Huo, XiaoJiao; Eijkelkamp, Niels et al. (2016) Critical role for Epac1 in inflammatory pain controlled by GRK2-mediated phosphorylation of Epac1. Proc Natl Acad Sci U S A 113:3036-41
Eijkelkamp, Niels; Steen-Louws, Cristine; Hartgring, Sarita A Y et al. (2016) IL4-10 Fusion Protein Is a Novel Drug to Treat Persistent Inflammatory Pain. J Neurosci 36:7353-63
Baameur, Faiza; Singhmar, Pooja; Zhou, Yong et al. (2016) Epac1 interacts with importin β1 and controls neurite outgrowth independently of cAMP and Rap1. Sci Rep 6:36370
LaVoy, Emily C P; Fagundes, Christopher P; Dantzer, Robert (2016) Exercise, inflammation, and fatigue in cancer survivors. Exerc Immunol Rev 22:82-93
Khandaker, Golam M; Dantzer, Robert (2016) Is there a role for immune-to-brain communication in schizophrenia? Psychopharmacology (Berl) 233:1559-73
Zhou, Wenjun; Kavelaars, Annemieke; Heijnen, Cobi J (2016) Metformin Prevents Cisplatin-Induced Cognitive Impairment and Brain Damage in Mice. PLoS One 11:e0151890
Liu, Yu-Ning; Peng, Yun-Li; -Liu, Lei et al. (2015) TNFα mediates stress-induced depression by upregulating indoleamine 2,3-dioxygenase in a mouse model of unpredictable chronic mild stress. Eur Cytokine Netw 26:15-25
Nixon, Scott E; González-Peña, Dianelys; Lawson, Marcus A et al. (2015) Analytical workflow profiling gene expression in murine macrophages. J Bioinform Comput Biol 13:1550010
Zhou, Wenjun; Dantzer, Robert; Budac, David P et al. (2015) Peripheral indoleamine 2,3-dioxygenase 1 is required for comorbid depression-like behavior but does not contribute to neuropathic pain in mice. Brain Behav Immun 46:147-53

Showing the most recent 10 out of 31 publications